// App-Quantinova.ai

FRI0333 : ACHIEVEMENT OF VERY LOW DISEASE ACTIVITY AND REMISSION TREATMENT TARGETS IS ASSOCIATED WITH REDUCED RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL

Researchers

Presenter

  • L. C. Coates

Principal Investigators

  • J. F. Merola

  • A. Kavanaugh

  • P. J. Mease

  • O. Davies

  • O. Irvin-Sellers

  • T. Nurminen

  • D. Van der Heijde

Medical Centers

  • Nuffield Orthopaedic Center, Oxford., Oxford, United Kingdom

  • Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, United States of America

  • Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Monheim am Rhein, Germany

  • Leiden University Medical Centre, Leiden, Netherlands

Locations

  • United Kingdom

  • United States

  • Germany

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • C reactive protein

  • Complement Factor B

  • Estrogen receptor alpha

  • Malondialdehyde

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT01087788

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved